investors hero

APIM Therapeutics has already raised more than EUR 9.5M from public and private sources since 2010. These include EUR 2.5M raised in the latest company round in December 2017. The round was led by current major investors Sarsia Seed and Norsk Innovasjonskapital III AS. Two major new investors have also participated, namely Bergens Forskningsstiftelse and Investinor AS, along with other company investors/shareholders including Birk Venture. The company will use the proceeds of the latest financing round to fund early clinical development of its drug lead ATX-101.

For more info on our investors, please visit their homepages below.